Pharming Group N.V. (PHAR)
USD 7.69
(0.52%)
USD 7.69
(0.52%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 244.07 Million USD | 10.36% |
| 2022 | 221.15 Million USD | 8.31% |
| 2021 | 204.18 Million EUR | -13.26% |
| 2020 | 235.38 Million EUR | 70.11% |
| 2019 | 138.37 Million EUR | -20.84% |
| 2018 | 174.8 Million EUR | -1.14% |
| 2017 | 176.82 Million EUR | 69.29% |
| 2016 | 104.45 Million EUR | 182.34% |
| 2015 | 36.99 Million EUR | 17.58% |
| 2014 | 31.46 Million EUR | -13.68% |
| 2013 | 36.45 Million EUR | 12.52% |
| 2012 | 32.39 Million EUR | -3.43% |
| 2011 | 33.54 Million EUR | -7.23% |
| 2010 | 36.15 Million EUR | -40.72% |
| 2009 | 60.99 Million EUR | -19.7% |
| 2008 | 75.95 Million EUR | -34.6% |
| 2007 | 116.14 Million EUR | 200.99% |
| 2006 | 38.58 Million EUR | 457.08% |
| 2005 | 6.92 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 206.08 Million USD | -12.57% |
| 2024 Q3 | 199.72 Million USD | -3.09% |
| 2024 Q1 | 235.72 Million USD | -6.52% |
| 2023 Q3 | 226.52 Million USD | -1.27% |
| 2023 Q4 | 252.17 Million USD | 11.32% |
| 2023 FY | 244.07 Million USD | 10.36% |
| 2023 Q1 | 223.65 Million USD | 1.13% |
| 2023 Q2 | 229.43 Million USD | 2.58% |
| 2022 Q1 | 198.77 Million USD | 10.22% |
| 2022 Q2 | 194.22 Million USD | -2.29% |
| 2022 Q3 | 182.06 Million USD | -6.26% |
| 2022 Q4 | 221.15 Million USD | 21.47% |
| 2022 FY | 221.15 Million USD | 8.31% |
| 2021 Q1 | 222.53 Million EUR | -5.46% |
| 2021 FY | 204.18 Million EUR | -13.26% |
| 2021 Q4 | 180.34 Million EUR | -13.04% |
| 2021 Q3 | 207.37 Million EUR | -3.03% |
| 2021 Q2 | 213.86 Million EUR | -3.9% |
| 2020 Q1 | 207.69 Million EUR | 50.1% |
| 2020 Q4 | 235.38 Million EUR | 9.5% |
| 2020 Q3 | 214.96 Million EUR | 0.84% |
| 2020 FY | 235.38 Million EUR | 70.11% |
| 2020 Q2 | 213.17 Million EUR | 2.64% |
| 2019 Q3 | 142.6 Million EUR | -2.25% |
| 2019 Q4 | 138.37 Million EUR | -2.97% |
| 2019 Q2 | 145.88 Million EUR | -0.45% |
| 2019 FY | 138.37 Million EUR | -20.84% |
| 2019 Q1 | 146.54 Million EUR | -16.17% |
| 2018 FY | 174.8 Million EUR | -1.14% |
| 2018 Q4 | 174.8 Million EUR | 4.08% |
| 2018 Q3 | 167.95 Million EUR | 3.25% |
| 2018 Q2 | 162.68 Million EUR | -5.12% |
| 2018 Q1 | 171.46 Million EUR | -3.03% |
| 2017 Q3 | 157.03 Million EUR | 14.21% |
| 2017 Q4 | 176.82 Million EUR | 12.6% |
| 2017 Q2 | 137.5 Million EUR | 25.54% |
| 2017 Q1 | 109.53 Million EUR | 4.86% |
| 2017 FY | 176.82 Million EUR | 69.29% |
| 2016 Q2 | 39.5 Million EUR | 0.33% |
| 2016 FY | 104.45 Million EUR | 182.34% |
| 2016 Q4 | 104.45 Million EUR | 174.84% |
| 2016 Q3 | 38 Million EUR | -3.79% |
| 2016 Q1 | 39.37 Million EUR | 6.42% |
| 2015 FY | 36.99 Million EUR | 17.58% |
| 2015 Q3 | 41.16 Million EUR | 64.82% |
| 2015 Q4 | 36.99 Million EUR | -10.13% |
| 2015 Q1 | 26.5 Million EUR | -15.75% |
| 2015 Q2 | 24.97 Million EUR | -5.79% |
| 2014 FY | 31.46 Million EUR | -13.68% |
| 2014 Q4 | 31.46 Million EUR | -0.34% |
| 2014 Q3 | 31.57 Million EUR | -19.66% |
| 2014 Q2 | 39.29 Million EUR | 9.51% |
| 2014 Q1 | 35.88 Million EUR | -1.56% |
| 2013 Q3 | 34.15 Million EUR | -10.46% |
| 2013 FY | 36.45 Million EUR | 12.52% |
| 2013 Q1 | 45.36 Million EUR | 40.02% |
| 2013 Q2 | 38.14 Million EUR | -15.91% |
| 2013 Q4 | 36.45 Million EUR | 6.73% |
| 2012 Q1 | 41.69 Million EUR | 24.29% |
| 2012 Q4 | 32.39 Million EUR | -5.72% |
| 2012 Q3 | 34.36 Million EUR | 0.0% |
| 2012 FY | 32.39 Million EUR | -3.43% |
| 2011 Q3 | 34.68 Million EUR | -6.79% |
| 2011 Q4 | 33.54 Million EUR | -3.29% |
| 2011 FY | 33.54 Million EUR | -7.23% |
| 2011 Q1 | 34.72 Million EUR | -3.97% |
| 2011 Q2 | 37.21 Million EUR | 7.17% |
| 2010 FY | 36.15 Million EUR | -40.72% |
| 2010 Q2 | 74 Million EUR | -0.76% |
| 2010 Q1 | 74.57 Million EUR | 22.27% |
| 2010 Q3 | 49.63 Million EUR | -32.94% |
| 2010 Q4 | 36.15 Million EUR | -27.15% |
| 2009 FY | 60.99 Million EUR | -19.7% |
| 2009 Q4 | 60.99 Million EUR | 0.0% |
| 2008 FY | 75.95 Million EUR | -34.6% |
| 2007 FY | 116.14 Million EUR | 200.99% |
| 2006 FY | 38.58 Million EUR | 457.08% |
| 2005 FY | 6.92 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 27.311% |
| Alkermes plc | 933.53 Million USD | 73.855% |
| Agenus Inc. | 462.29 Million USD | 47.204% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 93.974% |
| Aptorum Group Limited | 5.25 Million USD | -4543.051% |
| Ardelyx, Inc. | 130.76 Million USD | -86.653% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 48.98% |
| Bicycle Therapeutics plc | 224.41 Million USD | -8.761% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -87.446% |
| ChromaDex Corporation | 26.5 Million USD | -820.752% |
| Chimerix, Inc. | 19.74 Million USD | -1136.126% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -593.84% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -236.342% |
| CRISPR Therapeutics AG | 346.76 Million USD | 29.615% |
| Precision BioSciences, Inc. | 140.92 Million USD | -73.2% |
| Dyadic International, Inc. | 2.34 Million USD | -10327.569% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -1400.787% |
| Fortress Biotech, Inc. | 165.93 Million USD | -47.086% |
| Lantern Pharma Inc. | 2.73 Million USD | -8808.808% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -241.456% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -6816.748% |
| Incyte Corporation | 1.59 Billion USD | 84.671% |
| IO Biotech, Inc. | 17.55 Million USD | -1290.254% |
| Jaguar Health, Inc. | 45.86 Million USD | -432.144% |
| Novavax, Inc. | 2.57 Billion USD | 90.511% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -576.89% |
| Opthea Limited | 264.6 Million USD | 7.758% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -86.733% |
| ContextLogic Inc. | 206 Million USD | -18.482% |
| MiMedx Group, Inc. | 96.33 Million USD | -153.372% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -408.252% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -6816.43% |
| NextCure, Inc. | 14.99 Million USD | -1527.479% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -5938.422% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -3555.429% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -422.204% |
| Vaxcyte, Inc. | 167.44 Million USD | -45.76% |
| PDS Biotechnology Corporation | 33.25 Million USD | -633.853% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -3.766% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -1947.249% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -90.994% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3594.002% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3594.002% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -196.087% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -3574.138% |
| Acelyrin, Inc. | 86.35 Million USD | -182.646% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -18685.814% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -1597.427% |
| Summit Therapeutics Inc. | 125.25 Million USD | -94.858% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -2474.881% |
| Senti Biosciences, Inc. | 52.57 Million USD | -364.273% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -254.876% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -61.092% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -12378.17% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -18174.901% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -7.601% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -2505.669% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -7.311% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 50.643% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -2136.329% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -787.183% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -1916.349% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 49.841% |
| Immix Biopharma, Inc. | 3.72 Million USD | -6457.959% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -545.491% |
| MEI Pharma, Inc. | 8.35 Million USD | -2821.281% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -741.196% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 29.779% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -67.323% |
| Fortress Biotech, Inc. | 165.93 Million USD | -47.086% |
| Precigen, Inc. | 41.64 Million USD | -486.094% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -388.83% |
| AlloVir, Inc. | 45.01 Million USD | -442.204% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -87.263% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -77.121% |
| ImmuCell Corporation | 18.81 Million USD | -1197.224% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -764.71% |
| Onconetix, Inc. | 23.18 Million USD | -952.906% |
| PureTech Health plc | 125.58 Million USD | -94.352% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -2627.073% |
| Elevation Oncology, Inc. | 34.28 Million USD | -611.957% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -9882.536% |
| Seer, Inc. | 39.36 Million USD | -520.025% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -294.723% |
| Innoviva, Inc. | 568.55 Million USD | 57.071% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -796.404% |
| ESSA Pharma Inc. | 3.49 Million USD | -6883.349% |
| GlycoMimetics, Inc. | 6.9 Million USD | -3436.227% |
| GT Biopharma, Inc. | 6.63 Million USD | -3579.677% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 7.684% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 10.362% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -190.473% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -2397.166% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -798.351% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -7466.341% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -230.87% |
| Aptose Biosciences Inc. | 15.8 Million USD | -1443.916% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -2110.869% |
| Soligenix, Inc. | 7.27 Million USD | -3255.0% |
| Century Therapeutics, Inc. | 175.94 Million USD | -38.724% |
| Kura Oncology, Inc. | 51.66 Million USD | -372.442% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -101.244% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -5805.468% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -3590.329% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 3.375% |
| Autolus Therapeutics plc | 263.9 Million USD | 7.516% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -2228.496% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -174.668% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -420.423% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 30.829% |
| GRI Bio, Inc. | 2.69 Million USD | -8949.796% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -30047.915% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -685.028% |
| IGM Biosciences, Inc. | 220.17 Million USD | -10.853% |
| INmune Bio, Inc. | 18.86 Million USD | -1193.993% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 4.837% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -816.128% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -8878.534% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -7340.647% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -317.54% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -153.822% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 7.805% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 70.345% |
| Verastem, Inc. | 71.18 Million USD | -242.871% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -396.325% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -532.674% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -398.8% |
| Histogen Inc. | 5.69 Million USD | -4184.237% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -5465.321% |
| Surrozen, Inc. | 8.14 Million USD | -2896.599% |
| Organovo Holdings, Inc. | 2.74 Million USD | -8781.841% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -77665.423% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -334.063% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -1378.155% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -377.61% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -29417.521% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -92.601% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -2157.095% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -61.757% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -9260.978% |
| Apollomics, Inc. | 14.15 Million USD | -1624.532% |
| Amarin Corporation plc | 279.58 Million USD | 12.702% |
| Mesoblast Limited | 188.79 Million USD | -29.277% |
| Turnstone Biologics Corp. | 14.14 Million USD | -1625.141% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -35.005% |
| Synaptogenix, Inc. | 5.52 Million USD | -4314.04% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -3571.375% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -43.481% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2752.255% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -13788.356% |
| Exelixis, Inc. | 678.44 Million USD | 64.025% |
| Better Therapeutics, Inc. | 23.84 Million USD | -923.71% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -48.783% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 58.925% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2185.284% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -14932.68% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -527.002% |
| Gritstone bio, Inc. | 125.91 Million USD | -93.833% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1563.076% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -4696.441% |
| Avid Bioservices, Inc. | 275.66 Million USD | 11.461% |
| Insmed Incorporated | 1.66 Billion USD | 85.312% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -3072.241% |
| MediWound Ltd. | 27.18 Million USD | -797.756% |
| OmniAb, Inc. | 87.4 Million USD | -179.26% |
| Alector, Inc. | 487.66 Million USD | 49.951% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 39.504% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -1224.684% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -536.054% |
| Zai Lab Limited | 240.17 Million USD | -1.622% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 61.262% |
| Aura Biosciences, Inc. | 29.22 Million USD | -735.094% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -156.711% |
| Immunic, Inc. | 25.36 Million USD | -862.129% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -252.523% |
| Veracyte, Inc. | 93.71 Million USD | -160.431% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -9227.608% |
| FibroGen, Inc. | 585.72 Million USD | 58.33% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1304.09% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -37272.833% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -4215.707% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 96.812% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -2877.226% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -190.487% |
| TG Therapeutics, Inc. | 169.08 Million USD | -44.349% |
| Galecto, Inc. | 5.89 Million USD | -4039.637% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -2846.318% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 90.679% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -746.829% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1833.864% |
| XBiotech Inc. | 8.39 Million USD | -2806.669% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1563.076% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -358.956% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 32.782% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -807.875% |
| Theravance Biopharma, Inc. | 169 Million USD | -44.418% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 79.922% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 51.227% |
| Vaxxinity, Inc. | 30.94 Million USD | -688.757% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 74.902% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -3946.902% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 67.249% |
| NexImmune, Inc. | 5.08 Million USD | -4700.587% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -65618.078% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -7837.726% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 96.566% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -4635.576% |
| Scopus BioPharma Inc. | 7.45 Million USD | -3174.199% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -828.246% |
| Ainos, Inc. | 7.39 Million USD | -3200.861% |
| Pluri Inc. | 34.11 Million USD | -615.505% |
| Prothena Corporation plc | 135.01 Million USD | -80.772% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -0.399% |
| Celularity Inc. | 102.92 Million USD | -137.128% |
| Rallybio Corporation | 9.43 Million USD | -2486.615% |
| Cue Biopharma, Inc. | 24.44 Million USD | -898.458% |
| MeiraGTx Holdings plc | 319.99 Million USD | 23.725% |
| Omeros Corporation | 403.25 Million USD | 39.474% |
| Humacyte, Inc. | 114.67 Million USD | -112.835% |
| Immunocore Holdings plc | 228.15 Million USD | -6.975% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -4906.626% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -218.052% |
| Blueprint Medicines Corporation | 918.64 Million USD | 73.431% |
| CalciMedica, Inc. | 4.02 Million USD | -5959.409% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -1298.539% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -58.342% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -184.411% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 12.139% |
| Pulmatrix, Inc. | 15.96 Million USD | -1428.992% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -1447.41% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -891.925% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 2.685% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -380.591% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 79.839% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -667.936% |
| Nutriband Inc. | 1.07 Million USD | -22521.995% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -2195.429% |
| Vor Biopharma Inc. | 59.1 Million USD | -312.955% |
| Roivant Sciences Ltd. | 773.95 Million USD | 68.464% |
| Evogene Ltd. | 17.99 Million USD | -1256.715% |
| ProKidney Corp. | 29.21 Million USD | -735.409% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -239.089% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -34521.119% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 87.079% |
| CorMedix Inc. | 11.91 Million USD | -1948.017% |
| BioLineRx Ltd. | 50.7 Million USD | -381.387% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -63.304% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -175.973% |
| Atai Life Sciences N.V. | 49.16 Million USD | -396.467% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -683.483% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -1258.83% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -95.829% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -4216.82% |
| MediciNova, Inc. | 3.89 Million USD | -6171.866% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -1235.265% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -16125.658% |
| GeoVax Labs, Inc. | 3.51 Million USD | -6834.126% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 38.561% |
| Biomea Fusion, Inc. | 30.69 Million USD | -695.285% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 91.032% |
| Mereo BioPharma Group plc | 15.96 Million USD | -1429.088% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -682.26% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -315.911% |
| Absci Corporation | 58.3 Million USD | -318.621% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1181.358% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -661.253% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -230.767% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -178.995% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -622.751% |
| Allakos Inc. | 74.79 Million USD | -226.331% |
| Imunon, Inc. | 8.53 Million USD | -2761.205% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -984.721% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -112.585% |
| BioAtla, Inc. | 48.98 Million USD | -398.251% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2185.284% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -8682.764% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -86.88% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -1617.01% |
| XOMA Corporation | 145.58 Million USD | -67.656% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -625.005% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -254.969% |
| aTyr Pharma, Inc. | 31.59 Million USD | -672.456% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -294.793% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -442.807% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -404.262% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -8404.286% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -2891.817% |
| Akari Therapeutics, Plc | 4.58 Million USD | -5224.455% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1276.367% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 85.203% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -60327.87% |
| UroGen Pharma Ltd. | 243.52 Million USD | -0.226% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 23.985% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -8738.236% |
| Orgenesis Inc. | 35.53 Million USD | -586.852% |
| Entera Bio Ltd. | 1.37 Million USD | -17599.275% |
| GH Research PLC | 6.7 Million USD | -3542.337% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -3489.309% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -1196.468% |
| Xencor, Inc. | 283.55 Million USD | 13.925% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -8074.801% |
| Replimune Group, Inc. | 113.21 Million USD | -115.586% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -6396.27% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -135.751% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -60327.87% |
| Portage Biotech Inc. | 4.45 Million USD | -5384.787% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -16125.658% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -958.885% |
| OncoCyte Corporation | 49.29 Million USD | -395.097% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -5800.036% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -30505.379% |
| Purple Biotech Ltd. | 10 Million USD | -2339.51% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -4118.337% |
| scPharmaceuticals Inc. | 57.26 Million USD | -326.246% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1870.234% |
| HilleVax, Inc. | 78.9 Million USD | -209.309% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -4733.129% |
| Tharimmune, Inc. | 1.81 Million USD | -13347.207% |
| Genprex, Inc. | 3.25 Million USD | -7400.227% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -800.007% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -4561.44% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -118382.039% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -67972.615% |
| OKYO Pharma Limited | 7.42 Million USD | -3189.019% |
| Savara Inc. | 37.19 Million USD | -556.251% |
| Curis, Inc. | 57.61 Million USD | -323.65% |
| Daré Bioscience, Inc. | 26.32 Million USD | -826.982% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -522.638% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -16802.562% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -1072.357% |
| BeiGene, Ltd. | 2.23 Billion USD | 89.073% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -1046.432% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 6.983% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -1047.283% |
| Erasca, Inc. | 78.61 Million USD | -210.482% |
| bluebird bio, Inc. | 424.62 Million USD | 42.52% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -37148.723% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 87.086% |
| DBV Technologies S.A. | 42.8 Million USD | -470.264% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -37148.723% |
| Moderna, Inc. | 4.57 Billion USD | 94.662% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -3389.249% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -14638.708% |
| Molecular Templates, Inc. | 31.17 Million USD | -683.013% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -1329.836% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 58.498% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -96.035% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -789.576% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -569.5% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -338.704% |
| MacroGenics, Inc. | 154.2 Million USD | -58.276% |
| RenovoRx, Inc. | 4.46 Million USD | -5365.137% |
| Adicet Bio, Inc. | 37.12 Million USD | -557.524% |
| Prime Medicine, Inc. | 60.78 Million USD | -301.568% |
| Aditxt, Inc. | 28.53 Million USD | -755.449% |
| Adagene Inc. | 45.16 Million USD | -440.351% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -134970.088% |
| Quantum-Si incorporated | 26.63 Million USD | -816.5% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 65.011% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -7922.283% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -112.309% |
| SciSparc Ltd. | 1.59 Million USD | -15202.382% |
| Vericel Corporation | 127.7 Million USD | -91.123% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4285.942% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -185.94% |
| Generation Bio Co. | 171.63 Million USD | -42.209% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -2013.186% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -483.474% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 3.413% |
| Invivyd, Inc. | 51.71 Million USD | -371.976% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -165.363% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -3651.938% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -223.293% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -23805.289% |
| 2seventy bio, Inc. | 310.12 Million USD | 21.299% |
| ADMA Biologics, Inc. | 193.97 Million USD | -25.826% |
| Clene Inc. | 38.95 Million USD | -526.615% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -575.488% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 5.021% |
| GeoVax Labs, Inc. | 3.51 Million USD | -6834.126% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -28.282% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -1903.939% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -23.069% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -1901.451% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -407.312% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -361.901% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 34.008% |
| Evaxion Biotech A/S | 17.61 Million USD | -1285.402% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -51.665% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -59.331% |
| Trevena, Inc. | 48.26 Million USD | -405.725% |
| Surrozen, Inc. | 8.14 Million USD | -2896.599% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -1030.229% |
| Cingulate Inc. | 10.36 Million USD | -2255.72% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -8775.382% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -554.492% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -6705.288% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1756.068% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 23.054% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -882.225% |
| Clearmind Medicine Inc. | 3.61 Million USD | -6661.01% |
| Kronos Bio, Inc. | 54.2 Million USD | -350.311% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -418.83% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -972.39% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1116.048% |
| Statera Biopharma, Inc. | 22.67 Million USD | -976.328% |
| ImmunityBio, Inc. | 1.09 Billion USD | 77.616% |
| Korro Bio, Inc. | 51.75 Million USD | -371.62% |
| Kineta, Inc. | 7.22 Million USD | -3279.576% |
| BioVie Inc. | 9.7 Million USD | -2415.664% |
| Codexis, Inc. | 49.94 Million USD | -388.674% |
| Celularity Inc. | 102.92 Million USD | -137.128% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -153.59% |
| Celcuity Inc. | 51.45 Million USD | -374.388% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -70606.038% |
| Cibus, Inc. | 206.11 Million USD | -18.415% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -474.627% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -826.66% |
| IN8bio, Inc. | 8.77 Million USD | -2682.41% |
| Kodiak Sciences Inc. | 213.59 Million USD | -14.271% |
| Annexon, Inc. | 47.11 Million USD | -418.004% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -172.582% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -153.261% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -1682.986% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 90.625% |
| Eyenovia, Inc. | 19.78 Million USD | -1133.921% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -37.827% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -3077.62% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -912.793% |
| Arcellx, Inc. | 339.75 Million USD | 28.161% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -1951.378% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 0.597% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -2452.264% |
| Moolec Science SA | 13.94 Million USD | -1650.21% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -465.612% |
| Geron Corporation | 146.12 Million USD | -67.028% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -383.007% |
| Royalty Pharma plc | 6.29 Billion USD | 96.124% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -513.619% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -82803.541% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -9820.529% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -29.033% |
| Humacyte, Inc. | 114.67 Million USD | -112.835% |
| Structure Therapeutics Inc. | 29.05 Million USD | -740.153% |
| 89bio, Inc. | 59.96 Million USD | -307.039% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -822.318% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -20307.441% |
| Genelux Corporation | 8.42 Million USD | -2798.729% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -3459.991% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -79.045% |
| Notable Labs, Ltd. | 4.42 Million USD | -5413.282% |
| Liquidia Corporation | 73.13 Million USD | -233.716% |
| Mustang Bio, Inc. | 17.61 Million USD | -1285.283% |
| Immunovant, Inc. | 48.95 Million USD | -398.566% |
| Quantum-Si incorporated | 26.63 Million USD | -816.5% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -535.888% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -7765.711% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -230.449% |
| Acasti Pharma Inc. | 11.55 Million USD | -2011.906% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -979.6% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -8878.534% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -561.857% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -17809.119% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -3903.822% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -882.778% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -952.765% |
| PepGen Inc. | 34.63 Million USD | -604.782% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -1909.824% |
| United Therapeutics Corporation | 1.18 Billion USD | 79.354% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -3394.745% |
| Solid Biosciences Inc. | 38.45 Million USD | -534.648% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2752.255% |
| Immuneering Corporation | 12 Million USD | -1932.527% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -77665.423% |
| Silo Pharma, Inc. | 1.56 Million USD | -15453.283% |
| Belite Bio, Inc | 4.21 Million USD | -5696.082% |
| XOMA Corporation | 145.58 Million USD | -67.656% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -9952.43% |
| Bionomics Limited | 10.15 Million USD | -2302.596% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -1035.699% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -965.216% |
| uniQure N.V. | 624.01 Million USD | 60.887% |
| Cassava Sciences, Inc. | 14.19 Million USD | -1619.429% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -134970.088% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -43.417% |
| Forte Biosciences, Inc. | 3.66 Million USD | -6557.747% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -93564.207% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -3517.504% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -3077.62% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1304.09% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -2209.548% |
| Altimmune, Inc. | 16.54 Million USD | -1375.564% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 60.487% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -965.216% |
| Compugen Ltd. | 55.77 Million USD | -337.603% |
| Peak Bio, Inc. | 20.75 Million USD | -1076.065% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -120.955% |
| Benitec Biopharma Inc. | 4.96 Million USD | -4818.843% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -54.63% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -224.677% |
| Zura Bio Limited | 21.29 Million USD | -1046.313% |
| PolyPid Ltd. | 17.46 Million USD | -1297.258% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -117.149% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -224.677% |
| Instil Bio, Inc. | 99.8 Million USD | -144.56% |
| argenx SE | 444.95 Million USD | 45.146% |
| Immunome, Inc. | 28.65 Million USD | -751.675% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -2827.588% |
| Verona Pharma plc | 58.84 Million USD | -314.801% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -1586.402% |
| Shattuck Labs, Inc. | 14.85 Million USD | -1542.594% |
| CervoMed Inc. | 2.59 Million USD | -9302.804% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -4907.653% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1816.402% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -2216.782% |
| Moolec Science SA | 13.94 Million USD | -1650.21% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -10314.874% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -339.017% |
| AnaptysBio, Inc. | 364.28 Million USD | 33.0% |
| Design Therapeutics, Inc. | 11.95 Million USD | -1941.427% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1824.259% |
| NeurAxis, Inc. | 1.91 Million USD | -12660.392% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -526.986% |
| Lumos Pharma, Inc. | 13.33 Million USD | -1730.593% |
| Achilles Therapeutics plc | 19.08 Million USD | -1178.739% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -1586.402% |
| 180 Life Sciences Corp. | 5.38 Million USD | -4430.602% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -934.734% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -972.39% |
| Nutriband Inc. | 1.07 Million USD | -22521.995% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -697.676% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -1581.986% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 39.175% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -651.618% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1770.421% |
| Palisade Bio, Inc. | 2.73 Million USD | -8811.026% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -4546.354% |
| Beam Therapeutics Inc. | 478.38 Million USD | 48.98% |
| Neurogene Inc. | 36.54 Million USD | -567.797% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 38.668% |
| AEON Biopharma, Inc. | 159.88 Million USD | -52.652% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -412.22% |
| Sesen Bio, Inc. | 30.98 Million USD | -687.739% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -840.153% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -3110.551% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -24.694% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -27.084% |
| Athira Pharma, Inc. | 30.05 Million USD | -712.034% |
| Vaccinex, Inc. | 5.94 Million USD | -4007.59% |
| HCW Biologics Inc. | 15.05 Million USD | -1521.538% |
| XOMA Corporation | 145.58 Million USD | -67.656% |
| Nektar Therapeutics | 267.04 Million USD | 8.603% |
| Arvinas, Inc. | 644.6 Million USD | 62.136% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1276.367% |
| Merus N.V. | 102.15 Million USD | -138.934% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -66.773% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -156.595% |
| Rezolute, Inc. | 11.73 Million USD | -1980.049% |
| Clene Inc. | 38.95 Million USD | -526.615% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -8471.845% |
| BeyondSpring Inc. | 48.26 Million USD | -405.652% |
| Synlogic, Inc. | 32.89 Million USD | -641.976% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -1570.246% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -14837.148% |
| Peak Bio, Inc. | 20.75 Million USD | -1076.065% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -284.615% |
| Krystal Biotech, Inc. | 39.71 Million USD | -514.577% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 35.198% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -145.13% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -56303.59% |
| MannKind Corporation | 721.36 Million USD | 66.165% |
| Ikena Oncology, Inc. | 22.33 Million USD | -992.783% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -11600.527% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -137.911% |
| Gossamer Bio, Inc. | 249.14 Million USD | 2.037% |
| CohBar, Inc. | 1.03 Million USD | -23513.006% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -2183.403% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1181.358% |
| Legend Biotech Corporation | 589.93 Million USD | 58.627% |
| Mural Oncology plc | 37.92 Million USD | -543.517% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -84.017% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -10533.451% |
| Disc Medicine, Inc. | 22.87 Million USD | -966.986% |
| Champions Oncology, Inc. | 28.03 Million USD | -770.601% |
| REGENXBIO Inc. | 262.22 Million USD | 6.923% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -7165.479% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1847.287% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -1717.151% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -1051.016% |
| Vaxart, Inc. | 34.02 Million USD | -617.334% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -1097.066% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -755.44% |
| Cellectis S.A. | 249.57 Million USD | 2.205% |
| Longeveron Inc. | 5.33 Million USD | -4473.225% |
| Repare Therapeutics Inc. | 41.81 Million USD | -483.641% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 89.852% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -304.309% |
| Revolution Medicines, Inc. | 262.39 Million USD | 6.983% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -11483.911% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -2729.504% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -1968.24% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -1638.04% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -11246.955% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 95.261% |
| Denali Therapeutics Inc. | 122.96 Million USD | -98.493% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4285.942% |
| Veru Inc. | 32.81 Million USD | -643.837% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -3453.254% |
| Cingulate Inc. | 10.36 Million USD | -2255.72% |
| Passage Bio, Inc. | 39.26 Million USD | -521.652% |
| Context Therapeutics Inc. | 4.19 Million USD | -5722.748% |
| Exicure, Inc. | 8.54 Million USD | -2754.989% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -727.142% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -2227.608% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -1007.359% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -49.751% |
| Nuvalent, Inc. | 31.82 Million USD | -666.97% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -3736.644% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -287.282% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -1255.961% |
| OmniAb, Inc. | 87.4 Million USD | -179.26% |
| Anew Medical, Inc. | 8.24 Million USD | -2861.404% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -537.448% |
| Lipocine Inc. | 2.63 Million USD | -9174.598% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -829.023% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -506.966% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -816.128% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -183.299% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -4419.034% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -194.963% |
| Ocugen, Inc. | 23.98 Million USD | -917.692% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -425.94% |
| Q32 Bio Inc. | 233.12 Million USD | -4.695% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -2592.18% |
| Alumis Inc. Common Stock | 53.5 Million USD | -356.194% |
| Equillium, Inc. | 27.95 Million USD | -773.03% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -18.143% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -4237.792% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -3879.688% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -55.138% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -251.523% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -2347.043% |
| Dominari Holdings Inc. | 4.63 Million USD | -5165.868% |
| Edesa Biotech, Inc. | 1.84 Million USD | -13153.046% |
| vTv Therapeutics Inc. | 29.56 Million USD | -725.491% |
| Bio-Techne Corporation | 744.34 Million USD | 67.209% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -93.557% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 29.142% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -501.535% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -742.881% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -164.263% |
| Nkarta, Inc. | 105.6 Million USD | -131.13% |
| BioCardia, Inc. | 4.59 Million USD | -5217.495% |
| Iterum Therapeutics plc | 32.66 Million USD | -647.269% |